Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

Core Viewpoint - Algernon Health Inc. has increased its non-brokered private placement financing to CAD $750,000, with the third tranche closing at CAD $352,500 from the sale of 5,035,714 units at CAD $0.07 per unit, contributing to a total of CAD $739,500 raised from the sale of 10,564,286 units [2][3] Financing Details - The gross proceeds from the third tranche amounted to CAD $352,500, bringing the total financing to CAD $739,500 from the sale of 10,564,286 units [2][3] - The first and second tranches were closed on November 14, 2025, and November 28, 2025, respectively [2] Use of Proceeds - The proceeds from the offering will be utilized to advance the Alzheimer's Disease program, including the opening of the first U.S. Alzheimer's Disease clinic, as well as for general administrative expenses and working capital [3] Company Overview - Algernon Health is a Canadian healthcare company focused on brain optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions [6] - The company is also the parent of Algernon USA LLC, which will manage all U.S. neuroimaging operations [6]